Why flu season is so bad this year

Why flu season is so bad this year


If it seems like everyone around you is getting sick, you’re not imagining it. The flu season is hitting the United States unusually early and much harder than it usually does.

“I’m scared about what’s going to happen this flu season because I don’t think we’ve ever seen a coalition of multiple viruses kind of manifesting in this way before,” said Dr. Elizabeth Clayborne, an emergency medicine doctor and associate professor at the University of Maryland School of Medicine.

Clayborne family

Carlos Waters | CNBC

Covid precautions did lead to lower rates of flu-like illnesses compared to normal, pre-pandemic times. But now that much of America has abandoned preventive measures such as masking, more people are getting sick with seasonal illnesses.

“All of the patterns of intermingling and transmission of different viruses really slowed down from that shutdown,” said Dr. Andrea Berry, associate professor of pediatrics and medicine at University of Maryland School of Medicine. “As the world has opened up, the usual patterns are not quite the same.”

One of those flu-like illnesses is respiratory syncytial virus, or RSV, which is most severe in young children, the elderly and immune-compromised individuals.

There have been more reported cases of RSV in each week of October this year than any other week in the past two years, and doctors around the country are raising the alarm about hospitals being overwhelmed this season.

Just like RSV, cases of flu started surging earlier this year, with the Centers for Disease Control and Prevention reporting at least 1,600,000 cases, 13,000 hospitalizations and 730 deaths as of Oct. 29, which is high for this early in a typical flu season.

Clayborne’s 2-year-old and 4-year-old children both had RSV in late September, and her older daughter had to be taken to the emergency room for treatment.

Clayborne family

Carlos Waters | CNBC

“I know that [the flu and RSV are] common and it seems like a lot of kids get them,” Clayborne said. “But we see kids die all the time, and usually it’s from respiratory complications.”

There is currently no federally approved vaccine for treating RSV, but Pfizer reported in early November that its RSV vaccine candidate in its phase 3 trial, which was given to mothers during pregnancy, was nearly 70% effective at protecting severe symptoms in infants less than 6 months old.

Watch the video above to learn more about why this flu season is starting off with a surge and what we can do about it.



Source

Danish weight loss drug maker outlines ambitious 2030 strategy, ramping up pressure on Novo, Lilly
Health

Danish weight loss drug maker outlines ambitious 2030 strategy, ramping up pressure on Novo, Lilly

Celsopupo | Istock | Getty Images Zealand Pharma on Thursday outlined an ambitious five-year strategy for its anti-obesity portfolio Thursday, spotlighting how growing competition from smaller players is tightening the race for market leaders Novo Nordisk and Eli Lilly as more of these medicines near market entry. The new strategy, “Metabolic Frontier 2030,” comes as Zealand […]

Read More
Eli Lilly to build  billion manufacturing plant in Alabama to help make upcoming obesity pill, other drugs
Health

Eli Lilly to build $6 billion manufacturing plant in Alabama to help make upcoming obesity pill, other drugs

Eli Lilly CEO David A. Ricks speaks at a press conference at Generation Park in Houston, Monday, Sept. 23, 2025. The company announced plans for a $6.5 billion biomanufacturing plant in north Houston. (Raquel Natalicchio/Houston Chronicle via Getty Images) Raquel Natalicchio | Houston Chronicle | Getty Images Eli Lilly on Tuesday said it will spend […]

Read More
A biotech stock for investors scared to invest in the risky industry
Health

A biotech stock for investors scared to invest in the risky industry

Citigroup thinks investors should consider Ligand Pharmaceuticals for a more conservative bet on the biotech industry. The bank initiated the biotech stock at a buy rating and price target of $270, implying upside of 46% from Ligand’s Monday closing price of $184.67. Shares have soared nearly 79% this year. LGND YTD mountain LGND YTD chart […]

Read More